Press Release: Novartis: Sandoz receives FDA -2-

cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

References

1. Tyruko. Prescribing Information. Available at: : https://www.us.sandoz.com/sites/www.us.sandoz.com/files/media-library/documents/TYRUKO%20251958_US_LFT_P03%5B67%5D.pdf Prescribing Information

2. MS International Federation. What is MS? October 2021. Accessed May 17, 2022. https://www.msif.org/about-ms/what-is-ms/

3. Mayo Clinic. About Multiple Sclerosis. 2022. Accessed July 7, 2023. Available from: https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269.

*Tysabri is a registered trademark of Biogen MA, Inc.

# # #

About Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our vision is to be the world's leading and most valued generics company. Our broad portfolio of high-quality medicines covers major therapeutic areas.

Sandoz on social media:

LinkedIn: https://www.linkedin.com/company/sandoz

Twitter: https://twitter.com/sandoz_global

Facebook: https://www.facebook.com/sandozglobal/

Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

# # #

Sandoz Global Communications

North

Central America

+49 171 8384838 Vicki +1 201.213.6338 (mobile)

Joerg Allgaeuer joerg.allgaeuer@sandoz.com Crafton vicki.crafton@sandoz.com

Novartis Media Relations

E-mail: media.relations@novartis.com

North

Central America

Julie

Richard Jarvis +41 79 584 2326 Masow +1 862 579 8456

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line:

+41 61 324 7944

E-mail: investor.relations@novartis.com

North

Central America

Sloan

Samir Shah +41 61 324 7944 Simpson +1 862 345 4440

Parag

Nicole Zinsli-Somm +41 61 324 3809 Mahanti +1 973 876 4912

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

August 25, 2023 01:15 ET (05:15 GMT)